We’ll see what happens to the administration’s Part B proposal. Congress is not likely to take bold action, partly because drugmakers are a strong influence on both parties. That leaves the FDA and Administrator Scott Gottlieb, MD, as major players in efforts to rein in drug prices.
States are liberalizing their marijuana laws. Federal officials may be ready to take a step in that direction by ending the restrictions on a key ingredient, cannabidiol.